Login / Signup

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.

Bénédicte GaboritP AncelA E AbdullahF MauriceI AbdesselamA CalenA SoghomonianM HoussaysI VarletM EisingerA LasbleizF PeirettiC E BornetY LefurL PiniS RapacchiM BernardN ResseguierP DarmonF KoberA Dutour
Published in: Cardiovascular diabetology (2021)
EMPA effectively reduced liver fat in mice and humans without changing epicardial, myocardial fat or myocardial energetics, rebutting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors. Trial registration NCT, NCT03118336. Registered 18 April 2017, https://clinicaltrials.gov/ct2/show/NCT03118336.
Keyphrases